(Q36695648)

15 August 2017

Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines (English)

1 reference

diffuse large B-cell lymphoma

15 August 2017

1 reference

1 reference

1 reference

Elizabeth A Chrischilles

object named as

Elizabeth Chrischilles

6

0 references

Brian K Link

object named as

Brian K Link

1

0 references

author name string

John Brooks

2

1 reference

15 August 2017

Kara Wright

3

1 reference

15 August 2017

Xiaoyun Pan

4

1 reference

15 August 2017

Margaret Voelker

5

1 reference

15 August 2017

21 February 2011

1 reference

15 August 2017

1 reference

15 August 2017

52

1 reference

15 August 2017

6

1 reference

15 August 2017

994-1002

1 reference

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Utility of the SEER-Medicare data to identify chemotherapy use.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Development of a comorbidity index using physician claims data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Potential for cancer related health services research using a linked Medicare-tumor registry database.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601377

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21338277

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21338277

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21338277

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3109/10428194.2011.557167

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

21338277

1 reference